It is currently Fri Nov 28, 2014 9:14 am

News News of ThisIsMS

Site map of ThisIsMS » Forum : ThisIsMS

Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.

Very interesting ECTRIMS Abstract

After careful consideration, this abstract gets my vote for most interesting news from ECTRIMS 2006. To cut to the chase, this small study showed a reduction in annual relapse rate sustained over 5 years of 87.5% (from an average of 1.0 per year to an average of 0.125 per year)! The other good news is they say they have the funding to do a phase II trial.



Immunomodulation - Part I

Thursday, September 28, 2006, ...
Read more : Very interesting ECTRIMS Abstract | Views : 1755 | Replies : 4 | Forum : Drug Pipeline


Mitox and copaxone

A combo treatment for aggressive RR. This is the same combo that is being trialled in the UK after good results reported earlier this year.

No mention of EDSS. But this doesn't seem to matter to researchers - it's the number of relapses, reduction in Gd enhancing lesions etc that's important! Then they can generate lots of statistical data and avoid the real question - did the patient get any better?

Very Active Multiple Sclerosis ...
Read more : Mitox and copaxone | Views : 976 | Replies : 0 | Forum : General Discussion


Tysabri research

http://www.biogenidec.com/site/019_0.ht ... PR_143.htm

I would love to get my hands around the neck of the bastard who dreamt up this disease. As if physical disability wasn't bad enough they had to throw in cognitive problems!

Ian
Read more : Tysabri research | Views : 1469 | Replies : 0 | Forum : Tysabri (Antegren or Natalizumab)




Symadex Reverses EAE

Lucky mice... again.

Xanthus' Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model
Thursday September 28, 9:30 am ET
- Results Presented at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis -

CAMBRIDGE, Mass., Sept. 28 /PRNewswire/ -- Xanthus Pharmaceuticals, Inc., a privately-held drug development company, today presented data that Symadex(TM) reverses the clinical and pathological signs of chronic disease in an animal model for multiple sclerosis (MS). ...
Read more : Symadex Reverses EAE | Views : 1379 | Replies : 2 | Forum : Drug Pipeline






FTY720 Phase II data

Phase II data looks impressive. Probably 3 years from coming to market (my guess).

The following also looks interesting, but there is no data on EDSS (yet).

In addition to its anti-inflammatory effects, preclinical data suggest that FTY720 may have the potential to reduce neurodegeneration and enhance repair of the central nervous system (CNS) affected by MS.



Ian

http://c.moreover.com/click/here.pl?j654401602&w=464753
Read more : FTY720 Phase II data | Views : 1555 | Replies : 3 | Forum : Drug Pipeline


new rebif

Shame they couldn't have improved its efficacy! The bottom line is it still only reduces relapses by around 30%, but it's easier to take.

Ian

One-year Data From Phase III Trial Show That New Formulation of Rebif(r) Offers Substantial Improvement in Tolerability and Immunogenicity Profiles

Data Presented at 22nd ECTRIMS Congress in Madrid.


Serono announced today data from an ongoing two-year (96 weeks) Phase IIIb trial show that the new formulation of Rebif® (interferon beta-1a) ...
Read more : new rebif | Views : 1065 | Replies : 0 | Forum : Drug Pipeline




 

Login  •  Register


Statistics

Total posts 221803 • Total topics 23031 • Total members 14552


Contact us | Terms of Service